January 14, 2017 – Is there an increased risk of bladder cancer with pioglitazone-containing medicines? Some (most) drug regulatory agencies worldwide do think so. However, the actions taken vary considerably. The example of the French ANSM (L’Agence nationale de …

Pioglitazone: Too often ending in bladder cancer? Read more »

May 18, 2016 –  Over the last two years, biologics  targeting the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells), notably Nivolumab (Opdivo) and Pembrolizumab (Keytruda), have come to the clinic for the treatment of a selection of …

Hope for patients with urothelial carcinoma: Atezolizumab (Tecentriq) approved Read more »

November 27, 2014 – A drug which makes a wide range of cancers more vulnerable to the body’s immune system is “exciting” and may mark a new era, say doctors. The drug MPDL3280A strips cancer cells of the “camouflage” they use to …

Exciting new drug breakthrough in bladder cancer Read more »

June 20, 2011 – The American Food and Drug Administration (FDA) informed recently (on June 15, 2011) that the  use of the diabetes medication Pioglitazone [Actos] for more than one year may be associated with an increased risk of bladder …

Pioglitazone Containing Medicines: Ongoing Safety Review For A Potential Increased Risk of Bladder Cancer Read more »